Wall Street brokerages expect X4 Pharmaceuticals Inc (NASDAQ:XFOR) to post earnings of ($0.79) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for X4 Pharmaceuticals’ earnings. X4 Pharmaceuticals reported earnings per share of ($5.10) during the same quarter last year, which would indicate a positive year over year growth rate of 84.5%. The firm is scheduled to report its next earnings report on Monday, August 12th.
On average, analysts expect that X4 Pharmaceuticals will report full-year earnings of ($3.77) per share for the current fiscal year, with EPS estimates ranging from ($3.90) to ($3.64). For the next financial year, analysts forecast that the business will report earnings of ($3.80) per share, with EPS estimates ranging from ($3.84) to ($3.75). Zacks’ EPS calculations are an average based on a survey of analysts that cover X4 Pharmaceuticals.
X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($6.67) EPS for the quarter.
A hedge fund recently bought a new stake in X4 Pharmaceuticals stock. Polaris Venture Management Co. V L.L.C. bought a new position in shares of X4 Pharmaceuticals Inc (NASDAQ:XFOR) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 311,492 shares of the company’s stock, valued at approximately $5,423,000. X4 Pharmaceuticals accounts for approximately 4.6% of Polaris Venture Management Co. V L.L.C.’s portfolio, making the stock its 6th biggest holding. Polaris Venture Management Co. V L.L.C. owned approximately 2.51% of X4 Pharmaceuticals at the end of the most recent reporting period. 14.40% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:XFOR traded down $0.19 during midday trading on Monday, hitting $11.11. The company had a trading volume of 14,092 shares, compared to its average volume of 12,737. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.59 and a quick ratio of 1.59. X4 Pharmaceuticals has a 12-month low of $6.90 and a 12-month high of $29.46. The business has a fifty day simple moving average of $14.28.
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Further Reading: How Do Mutual Funds Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.